Contact us
For General Inquiries Email: info@nirmidas.com
For Product Support Email: support@nirmidas.com
Nirmidas Biotech, Inc, in collaboration with Stanford’s Departments of Pathology and Medicine, received an award from the National Institute of Health on March 24, 2017.The grant is for a nanoscale plasmonic-gold platform for specific diagnosis of Zika and differentiation from other flavivirus infections. The underlying technology for this grant was recently published in Nature Medicine.Read more
ASSAYS AND SCREENS By Hongjiang Li appeared in BioCentury InnovationsTECHNOLOGY: Diagnostic assaysA plasmonic chip-based microarray could help aid the differential diagnosis of Zika and dengue infections. The assay utilized a gold plasmonic chip-based microarray printed with Zika virus genome polyprotein (GP1) and dengue viral particles for capture of virus-reactive antibodies from human... Read m
For research use onlyZika/Dengue Assay Kit ExampleNirmidas Biotech Inc. announces the availability of three pGOLD-Zika/Dengue IgG/IgM/IgA Assay kits for rapid, simultaneous, multiplexed detection of IgG, IgM and IgA antibodies against Zika virus (ZIKV) and Dengue virus (DENV), each requiring only 1 micro-liter of patient sera. A unique IgG avidity test against both ZIKV and DENV is also developed.
Press Release - Palo AltoNirmidas Biotech and Hongjie Dai, PhD, in the Department of Chemistry and Benjamin Pinsky, MD, PhD, in the Departments of Pathology and Medicine at Stanford University have developed a multiplexed serological test for rapidly distinguishing Zika virus (ZIKV) infection from dengue virus (DENV) infection, in both acute and convalescent patients.This breakthrough was publishe
Read more here: http://www.prweb.com/releases/prweb14120231.htm
Nirmidas has relocated in Palo Alto to a new office space with 4,500 Sq Ft, enabling further growth, development and commercialization of our pGold and Assay technology, as well as NIR-II imaging technology.